215 related articles for article (PubMed ID: 27179248)
1. Cardiovascular side-effects and insulin secretion after intravenous administration of radiolabeled Exendin-4 in pigs.
Rydén A; Nyman G; Nalin L; Andreasson S; Velikyan I; Korsgren O; Eriksson O; Jensen-Waern M
Nucl Med Biol; 2016 Jul; 43(7):397-402. PubMed ID: 27179248
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs.
Nalin L; Selvaraju RK; Velikyan I; Berglund M; Andréasson S; Wikstrand A; Rydén A; Lubberink M; Kandeel F; Nyman G; Korsgren O; Eriksson O; Jensen-Waern M
Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1800-10. PubMed ID: 24643781
[TBL] [Abstract][Full Text] [Related]
3. The effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant model.
Sahraoui A; Winzell MS; Gorman T; Smith DM; Skrtic S; Hoeyem M; Abadpour S; Johansson L; Korsgren O; Foss A; Scholz H
PLoS One; 2015; 10(3):e0121204. PubMed ID: 25793295
[TBL] [Abstract][Full Text] [Related]
4. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats.
Wu L; Olverling A; Huang Z; Jansson L; Chao H; Gao X; Sjöholm Å
Clin Sci (Lond); 2012 Apr; 122(8):375-84. PubMed ID: 22054347
[TBL] [Abstract][Full Text] [Related]
5. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.
Arakawa M; Ebato C; Mita T; Hirose T; Kawamori R; Fujitani Y; Watada H
Biochem Biophys Res Commun; 2009 Dec; 390(3):809-14. PubMed ID: 19836346
[TBL] [Abstract][Full Text] [Related]
6. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Parkes DG; Pittner R; Jodka C; Smith P; Young A
Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
8. Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats.
Malendowicz LK; Macchi C; Nussdorfer GG; Nowak KW; Zyterska A; Ziolkowska A
Int J Mol Med; 2003 Jun; 11(6):763-6. PubMed ID: 12736719
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.
Bandara N; Zheleznyak A; Cherukuri K; Griffith DA; Limberakis C; Tess DA; Jianqing C; Waterhouse R; Lapi SE
Mol Imaging Biol; 2016 Feb; 18(1):90-8. PubMed ID: 25987465
[TBL] [Abstract][Full Text] [Related]
10. Exendin-4 exerts its effects through the NGF/p75NTR system in diabetic mouse pancreas.
Gezginci-Oktayoglu S; Bolkent S
Biochem Cell Biol; 2009 Aug; 87(4):641-51. PubMed ID: 19767827
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.
Degn KB; Brock B; Juhl CB; Djurhuus CB; Grubert J; Kim D; Han J; Taylor K; Fineman M; Schmitz O
Diabetes; 2004 Sep; 53(9):2397-403. PubMed ID: 15331551
[TBL] [Abstract][Full Text] [Related]
12. Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes.
Thazhath SS; Marathe CS; Wu T; Chang J; Khoo J; Kuo P; Checklin HL; Bound MJ; Rigda RS; Horowitz M; Jones KL; Rayner CK
Diab Vasc Dis Res; 2017 Jan; 14(1):59-63. PubMed ID: 27941058
[TBL] [Abstract][Full Text] [Related]
13. Protocol for Clinical GLP-1 Receptor PET/CT Imaging with [
Tokgöz S; Boss M; Prasad S; Shah P; Laverman P; van Riel M; Gotthardt M
Methods Mol Biol; 2023; 2592():143-153. PubMed ID: 36507990
[TBL] [Abstract][Full Text] [Related]
14. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes.
Dupré J; Behme MT; McDonald TJ
J Clin Endocrinol Metab; 2004 Jul; 89(7):3469-73. PubMed ID: 15240633
[TBL] [Abstract][Full Text] [Related]
15. Durable islet effects on insulin secretion and protein kinase A expression following exendin-4 treatment of high-fat diet-fed mice.
Winzell MS; Ahrén B
J Mol Endocrinol; 2008 Feb; 40(2):93-100. PubMed ID: 18234911
[TBL] [Abstract][Full Text] [Related]
16. Exendin-4 dose-dependently stimulates somatostatin and insulin secretion in perfused rat pancreas.
Egido EM; Silvestre RA; Hernández R; Marco J
Horm Metab Res; 2004 Sep; 36(9):595-600. PubMed ID: 15486809
[TBL] [Abstract][Full Text] [Related]
17. In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4.
Selvaraju RK; Velikyan I; Johansson L; Wu Z; Todorov I; Shively J; Kandeel F; Korsgren O; Eriksson O
J Nucl Med; 2013 Aug; 54(8):1458-63. PubMed ID: 23761918
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.
Luo Y; Pan Q; Yao S; Yu M; Wu W; Xue H; Kiesewetter DO; Zhu Z; Li F; Zhao Y; Chen X
J Nucl Med; 2016 May; 57(5):715-20. PubMed ID: 26795291
[TBL] [Abstract][Full Text] [Related]
19. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo.
Nguyen HN; Wey SP; Juang JH; Sonaje K; Ho YC; Chuang EY; Hsu CW; Yen TC; Lin KJ; Sung HW
Biomaterials; 2011 Apr; 32(10):2673-82. PubMed ID: 21256586
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
